The Global Health Body Sounds Concern Over Severe Lack of Obesity Jabs

Under 10% of patients who could benefit from weight-loss injections like Wegovy can access them, states the World Health Organization as it releases its initial recommendations on the medications.

Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for increased and just access to these injectable treatments.

Per estimates, over two billion will be living with obesity by 2030 if no action is taken.

"Our new guidance affirms that excess weight is a lifelong illness that can be managed with holistic and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and logistical bottlenecks are key barriers to broad availability to the injections that can help people shift substantial body mass, says the agency.

Skinny Jab Supply Crisis

Despite the current most optimistic outlook, the production of such drugs could only cover about 100 million people – less than 10% of those who need them, as stated by the health organization.

The guideline encourages nations and manufacturers to widen access, via approaches such as licensing agreements.

Exclusive production rights on semaglutide – the main component of the drug Wegovy – is set to lapse in a number of nations in 2026.

The Way Obesity Injections Work

GLP-1 drugs replicate a natural hormone to delay gastric emptying, curb appetite and boost satiety so individuals consume fewer calories.

People typically see weight reduction in the initial weeks of beginning the once-weekly jabs.

Evidence points to patients may regain a significant portion after a year of halting the drug, as their usual hunger resume.

Being above a healthy weight increases your likelihood for developing health problems, including diabetes, cardiovascular issues, stroke, and specific cancers.

Excess weight concerns people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.